Merck & Co., Inc. (NYSE:MRK) Shares Sold by Murphy Pohlad Asset Management LLC

by · The Markets Daily

Murphy Pohlad Asset Management LLC decreased its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 3.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,208 shares of the company’s stock after selling 808 shares during the quarter. Murphy Pohlad Asset Management LLC’s holdings in Merck & Co., Inc. were worth $2,863,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Patron Partners LLC boosted its position in Merck & Co., Inc. by 2.1% during the 1st quarter. Patron Partners LLC now owns 10,580 shares of the company’s stock valued at $1,396,000 after purchasing an additional 222 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its position in Merck & Co., Inc. by 10.0% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 247,338 shares of the company’s stock valued at $32,636,000 after purchasing an additional 22,578 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Merck & Co., Inc. by 16.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 63,101 shares of the company’s stock valued at $7,211,000 after purchasing an additional 8,985 shares during the period. AMF Tjanstepension AB boosted its position in Merck & Co., Inc. by 114.2% during the 3rd quarter. AMF Tjanstepension AB now owns 802,384 shares of the company’s stock valued at $91,205,000 after purchasing an additional 427,831 shares during the period. Finally, M&G Plc acquired a new position in Merck & Co., Inc. during the 1st quarter valued at approximately $48,921,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Citigroup reduced their price objective on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Friday, October 25th. UBS Group reduced their price target on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Wolfe Research upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Truist Financial reduced their price target on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Finally, Sanford C. Bernstein began coverage on Merck & Co., Inc. in a research report on Thursday, October 17th. They set a “market perform” rating and a $115.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $129.93.

Get Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 0.4 %

NYSE:MRK opened at $101.87 on Friday. The firm has a market capitalization of $258.02 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 1.50 and a beta of 0.39. Merck & Co., Inc. has a 1-year low of $98.60 and a 1-year high of $134.63. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80. The business’s fifty day moving average price is $112.29 and its 200 day moving average price is $120.87.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.07. The firm had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. Merck & Co., Inc.’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.13 earnings per share. On average, sell-side analysts forecast that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading